Evaluate the efficacy and safety of Lifitegrast in subjects with dry eye disease and a recent history of artificial tear use.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
711
Lifitegrast Ophthalmic Solution 5%, BID for 84 days
Placebo to match active treatment, BID for 84 days
Change From Baseline in Patient-Reported Eye Dryness Score to Day 84
Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).
Time frame: Baseline to Day 84
Change From Baseline in Patient-Reported Eye Dryness Score to Day 14 and Day 42
Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).
Time frame: Baseline to Day 14 and Day 42
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Alabama at Birmingham, UAB School of Optometry
Birmingham, Alabama, United States
Arizona Eye Center
Chandler, Arizona, United States
Sall Research Medical Center
Artesia, California, United States
United Medical Research Institute
Inglewood, California, United States
North Valley Eye Medical Group, Inc
Mission Hills, California, United States
Montebello Medical Eye Center, Inc.
Montebello, California, United States
Eye Research Foundation
Newport Beach, California, United States
Arch Health Partners
Poway, California, United States
Martel Eye Medical Group
Rancho Cordova, California, United States
Shasta Eye Medical Group, Inc.
Redding, California, United States
...and 31 more locations